cholesterol - CarboHyde

Cyclodextrins: Only Pharmaceutical Excipients or Full-Fledged Drug Candidates?

Nov 25, 2022Tamas SohajdaToday's cyclodextrinatherosclerosis, cholesterol, infectious diseases, lipid, neurodegenerative diseases, rare disease

What is the future of cyclodextrin: excipient or API?
A very timely review from University of Debrecen (Gyorgy Panyi, Florina Zakany, et al.) discussing #molecular targets, mechanism of action, and ongoing research in several diseases. Which do you think holds the future?

See the full article here

Cyclodextrins applied to the treatment of lysosomal disorders

Nov 14, 2022Tamas Sohajdadrug development, drug discoverycholesterol, Niemann-Pick disease, ototoxicity, rare disease

We have been waiting for this review for a long time. #cyclodextrin in lysosomal storage diseases!
Huge thanks to Kumamoto University, JAPAN and Saga University

See the full article

lysosomal storage disease, lipid trafficking, Niemann-Pick disease type C, cyclodextrin, cholesterol, ototoxicity

Cyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Nov 7, 2022Tamas Sohajdadrug developmentcholesterol, clinical trial, cyclodextrin, rare disease

Cyclo Therapeutics, Inc. (Caroline Hastings, Benny Liu, Bryan Hurst, Gerald Cox and Sharon Hrynkow) Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Artikle: https://www.sciencedirect.com/science/article/pii/S109671922200419X

Cyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Inclusion Solves Insolubility —Translational Research Cycle from Bedside to Bench and Bench to Bedside for Drug Development Targeting Niemann-Pick Disease Type C

Oct 21, 2022Tamas Sohajdadrug developmentcholesterol, rare disease, toxicity, translational research

Tetsumi Irie form Kumamoto University explains the differences in the mechanisms of action for HPBCD and HPGCD in the treatment of Niemann-Pick C.

Full article: https://doi.org/10.1248/yakushi.21-00215

Cyclodextrin boostered-high density lipoprotein for antiatherosclerosis by regulating cholesterol efflux and efferocytosis

Oct 11, 2022Tamas Sohajdadrug delivery, drug developmentcardiovascular, cholesterol

The cyclodextrin-supported atherosclerosis treatment field is getting crowded. Here is a unique approach using polyethylene glycol succinate (TPGS)-CD, which was adsorbed on rHDL, then modified with Apo-Ai, and coated with hyaluronan to obtain HT-rHDL. Piece of cake!
China Pharmaceutical University

Full article on ScienceDirect
https://doi.org/10.1016/j.carbpol.2022.119632

Cyclodextrin derivatives in the treatment or prevention of lysosomal neurodegenerative diseases

Oct 5, 2022Tamas Sohajdadrug developmentcholesterol, rare disease

We are happy to report on the acceptance of Tamas Sohajda‘s new patent on the use of single isomer chemically modified cyclodextrin for treating lysosomal storage diseases. Sugammadex and similar compounds are mentioned as potential active ingredients in this patent.

Espacenet link